HHS Invests in Modernizing U.S. Manufacturing Capacity for Pandemic Influenza Vaccine | HHS.gov

HHS Invests in Modernizing U.S. Manufacturing Capacity for Pandemic Influenza Vaccine | HHS.gov

HHS Invests in Modernizing U.S. Manufacturing Capacity for Pandemic Influenza Vaccine Through a public-private partnership between ASPR’s Biomedical Advanced Research and Development Authority (BARDA) and Sanofi Pasteur, HHS announced this week a six-year, $226 million contract to increase capacity to produce recombinant influenza vaccine in the United States. The contract is in accordance with the September 19 presidential executive order to enhance national security and the public health by modernizing influenza vaccines and technologies. Read Release